New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsGenetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapyFibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinomaGenetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapiesNavigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnosticsSWI/SNF chromatin remodeling complexes and cancerPreclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationNTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesThe rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?TRKing down an old oncogene in a new era of targeted therapyTargeted therapy in biliary tract cancers-current limitations and potentials in the future.Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic CholangiocarcinomaMultiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaThe landscape of kinase fusions in cancerCRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Cholangiocarcinoma: molecular pathways and therapeutic opportunitiesMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinomaMolecular diagnosis of intrahepatic cholangiocarcinoma.Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.Liver cancer oncogenomics: opportunities and dilemmas for clinical applications.Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation.A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencingNTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic CancersIntratumoral heterogeneity of intrahepatic cholangiocarcinoma.Multimodal treatment strategies for advanced hilar cholangiocarcinoma.Molecular pathogenesis of intrahepatic cholangiocarcinoma.Detecting and targetting oncogenic fusion proteins in the genomic era.Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.New Horizons for Precision Medicine in Biliary Tract Cancers.Emerging molecular targets and therapy for cholangiocarcinoma.
P2860
Q26751224-E74C070C-DD84-40E5-90CA-507968F7DD07Q26751655-1ADBF873-96D4-4045-BBAA-419B9F104D64Q26824969-7BC5C109-A068-407F-BE7D-046A1A653E2FQ26852049-59959FBD-BD05-4AFC-B01D-340731ED98ADQ26864332-5C4225E8-5AAD-4A62-A437-46CE786ED96DQ26998657-B6A47BA4-E2DA-4D6C-A005-2A16EB2F480AQ27322795-911781D0-5153-4933-894B-1BD4BE9B50D6Q27853306-5D698E4F-4DEF-4130-8513-EFBDCE794172Q28066821-4DCF407D-7E52-412A-A2B6-AABBE887B469Q28074145-868549D9-F69C-4068-ACAB-81E5DEDF60B8Q28254287-B3E6335F-9201-439A-9305-7DEAAF862196Q30234532-F7BF73A8-853C-458C-8E0E-D88ED98B070DQ30405398-23FC5DD6-04D5-47A7-82FC-5883BF940235Q32173000-8FB33E58-90B5-4351-9151-F93E9F6F772FQ33656860-70927160-4B56-4A12-9DA9-A67DC55D610CQ33763540-DCE08B0D-773C-4821-A5D0-661D9DDD92DBQ33888883-54904B43-71A3-4D7E-8EA8-11B19AE5091CQ34437602-6B583010-BED9-4780-A102-35E67979B243Q34499647-1FA27930-4EB8-414C-B549-1DE8B057ABC7Q34550326-8AFB3154-099A-422A-922C-ACA74A09C353Q34959174-047C16E5-EA09-4386-967C-31682CC05B25Q35136424-03B69D7E-A5CE-4796-AAE0-CB20E56096B0Q35215602-16546B51-996F-44A9-A00E-F258C9CF6DF6Q35592221-4B504B30-BA52-4461-89D3-107766DF4923Q35820533-C9474486-B1AE-4BFB-8345-A7C5D32BB00EQ35913384-85FB1CC5-B5BF-4B19-8FB9-9BF0AC773621Q35921330-72A6AFC0-1F51-4288-9C8D-D2E886FC0A21Q35934963-54C80ED7-137A-451F-BD15-8C629308B456Q36096044-6DA1738B-CDB5-401A-B4D2-9988FAFCD582Q36113790-59D16826-6842-4563-9B4F-1FCFD4B3D28DQ36629492-1F253F3B-3A4B-43CE-97F8-2AA40F82141FQ36884411-6A43C9FA-6D91-4B2F-A973-CABAB18C2325Q37631655-F79CB0A5-8BE5-46D5-A951-84BB2D258FAAQ37716471-F2A78B97-B4FF-43D4-BED2-7E57962BEEE2Q38222988-1073F5D5-CB23-44B6-9B1B-B9CD032E3A2EQ38244965-37DB74F1-F529-48C8-B730-0FD927F07527Q38336067-05A6C8AC-4E68-46F8-9C10-E84BC54F5CB6Q38354294-FEF42EA0-C8BF-4EAA-983C-33F5A94995F0Q38619219-556F5DF1-724F-4A5C-AA0C-CFE18E6C6DBCQ38642455-D3430714-7F35-4D5D-8FC4-848DAE66D032
P2860
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
New routes to targeted therapy ...... by next-generation sequencing.
@ast
New routes to targeted therapy ...... by next-generation sequencing.
@en
type
label
New routes to targeted therapy ...... by next-generation sequencing.
@ast
New routes to targeted therapy ...... by next-generation sequencing.
@en
prefLabel
New routes to targeted therapy ...... by next-generation sequencing.
@ast
New routes to targeted therapy ...... by next-generation sequencing.
@en
P2093
P2860
P1433
P1476
New routes to targeted therapy ...... by next-generation sequencing.
@en
P2093
Chaitanya Churi
Christine E Sheehan
Daniel V T Catenacci
David M Jones
Deborah Morosini
Doron Lipson
Gary Palmer
Geoff A Otto
Janne V Rand
P2860
P304
P356
10.1634/THEONCOLOGIST.2013-0352
P577
2014-02-21T00:00:00Z